Lyssikatos Joseph P (CIK 1967150) reported 28 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-02-17). Recent activity: Buy ELVN (18,750 shares), Sell ELVN (5,000 shares), Sell ELVN (5,491 shares), Sell ELVN (14,509 shares), Sell ELVN (7,500 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-17 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Buy | 18,750 | $0 |
| 2026-02-10 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 5,000 | $145,200 |
| 2026-01-22 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 5,491 | $144,798 |
| 2026-01-22 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 14,509 | $390,292 |
| 2026-01-12 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 7,500 | $150,975 |
| 2026-01-12 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 33,802 | $842,346 |
| 2026-01-12 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 41,198 | $1.0M |
| 2026-01-12 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 50,000 | $1.5M |
| 2025-12-23 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 5,000 | $84,200 |
| 2025-11-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 12,008 | $267,778 |
| 2025-11-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 492 | $11,360 |
| 2025-10-22 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 12,500 | $276,000 |
| 2025-09-30 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 4,000 | $81,000 |
| 2025-09-25 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 1,500 | $30,045 |
| 2025-09-23 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 4,870 | $93,066 |
| 2025-09-23 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 2,130 | $42,643 |
| 2025-08-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 5,000 | $98,100 |
| 2025-08-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 7,500 | $150,075 |
| 2025-07-23 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 11,924 | $265,428 |
| 2025-07-23 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 576 | $13,190 |
| 2025-06-24 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 12,500 | $267,500 |
| 2025-06-05 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 7,500 | $150,225 |
| 2025-05-21 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 5,000 | $81,550 |
| 2025-05-05 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 5,030 | $100,952 |
| 2025-05-05 | Enliven Therapeutics, Inc. (ELVN) | CHIEF SCIENTIFIC OFFICER | Sell | 2,470 | $49,425 |
Source: SEC Form 4 filings · as of 2026-02-17